These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3238937)

  • 1. [Study of middle molecular weight fraction in the plasma of patients with uremia using high performance liquid chromatography and thin layer chromatography].
    Kovalishin IaF; Nikolaev VG; Baran EIa; Dudar' IA; Iushko LA
    Vopr Med Khim; 1988; 34(6):23-6. PubMed ID: 3238937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uremic middle molecules: analytical study of middle molecular weight fractions subpeak b4-2.
    Le Moel G; Strecker G; Cueille G; Boudet J; Man NK; Galli A; Agneray J
    Artif Organs; 1981; 4 Suppl():17-21. PubMed ID: 7295087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical study for separation of middle molecules.
    Saito A; Kanazawa I; Chung TG; Maeda K
    Artif Organs; 1981; 4 Suppl():13-6. PubMed ID: 6975092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of plasma middle molecular fraction in uremic patients.
    Kovalishin YaF
    Biomater Artif Cells Artif Organs; 1987; 15(3):605-10. PubMed ID: 3440134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technical aspects on middle molecules: separation, isolation, and identification.
    Cueille G; Man NK; Sausse A; Farges JP; Funck-Brentano JL
    Artif Organs; 1981; 4 Suppl():8-12. PubMed ID: 7295100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromatographic analysis of middle molecules in plasma ultrafiltrates of uraemic patients.
    Popławski A; Myśliwiec M
    Nephrol Dial Transplant; 1993; 8(2):188. PubMed ID: 8384345
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effect of chromatographic fractions of blood ultrafiltrates of patients with chronic uremia on the fibrinolytic activity]].
    Popławski A; Myśliwiec M; Soszka J
    Pol Tyg Lek; 1990 Oct 1-8; 45(40-41):810-3. PubMed ID: 2096374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of phagocytosis by a middle molecular fraction from ultrafiltrate.
    Ringoir SM; van Landschoot N; de Smet R
    Clin Nephrol; 1980 Mar; 13(3):109-12. PubMed ID: 7379359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low molecule and middle molecule metabolites with haemodynamic activity in the ultrafiltrate from uraemic patients (author's transl).
    Pogglitsch H; Petek W; Waller J; Stübchen-Kirchner H
    Wien Klin Wochenschr; 1977 Dec; 89(24):812-9. PubMed ID: 595605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of middle molecule compounds.
    Zimmerman L; Jörnvall H; Bergström J; Fürst P; Sjövall J
    Artif Organs; 1981; 4 Suppl():33-6. PubMed ID: 7295092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biochemical definition of uremia].
    Ringoir S
    Verh K Acad Geneeskd Belg; 1981; 43(2):105-19. PubMed ID: 7314875
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of blood toxicity in chronic uremia by an improved chromatographic method.
    Politi L; D'Angelo AR; Caramia M; Molinaro M; Nicoletti R; Cerulli N; Moriggi M; Scandurra R
    Clin Exp Dial Apheresis; 1981; 5(3):277-84. PubMed ID: 7333038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Point of micropreparative high pressure liquid chromatography and thin-layer chromatography for the identification of indole compounds in human plasma (author's transl)].
    Trefz FK; Byrd DJ; Kochen W
    J Clin Chem Clin Biochem; 1976 Feb; 14(2):65-72. PubMed ID: 1249527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amino acid composition of uremic middle and low molecular weight retention products.
    Bazilinski N; Shaykh M; Ahmed S; Musiala T; Williams RH; Poulos A; Dubin A; Dunea G
    Adv Exp Med Biol; 1987; 223():197-204. PubMed ID: 3447436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uremic middle molecules in non-dialyzed azotemic patients: relation to symptoms and clinical biochemistries.
    Asaba H; Alvestrand A; Bergström J; Fürst P; Yahiel V
    Clin Nephrol; 1982 Feb; 17(2):90-5. PubMed ID: 7067171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methodology for identification of serum middle molecules.
    Buzio C; Montagna G; Calderini C; Manari A; Migone L
    Artif Organs; 1981; 4 Suppl():22-7. PubMed ID: 7295090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Separation, identification of uremic middle molecules, and preliminary study on their toxicity.
    Li G; Chu J; Liu X; Yuan Z
    Clin Chim Acta; 2004 Dec; 350(1-2):89-98. PubMed ID: 15530464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Separation, isolation and amino acid composition of uremic peptides.
    Shaykh M; Dubin A; Dunea G; Mamdani B; Ahmed S
    Clin Physiol Biochem; 1984; 2(1):1-13. PubMed ID: 6488692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum middle molecules in uremia.
    Buzio C; Manari A; Calderini C; Montagna G; Migone L
    Artif Organs; 1981; 4 Suppl():143-50. PubMed ID: 7295081
    [No Abstract]   [Full Text] [Related]  

  • 20. [Detection of uremic peaks by high performance liquid chromatography and their behavior].
    Koide K; Toyama J; Inoue N; Koshikawa S; Akizawa T; Takahashi K; Hidaka S; Yamane Y; Nakao M; Uehara Y
    Nihon Jinzo Gakkai Shi; 1986 Aug; 28(8):1101-10. PubMed ID: 3807043
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.